Head-to-head evidence
Henagliflozin vs Saxagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Henagliflozin
Developed by Jiangsu Hengrui Pharmaceuticals
NCT03159052 · Phase 3 · status unknown
This was a randomized, quadruple-blind, placebo-controlled trial (n=450). The primary endpoint, HbA1c change at 24 weeks, was clearly met: both the 5 mg and 10 mg doses reduced HbA1c significantly more than placebo (p<.001 for each).
Next expected readout: December 2026 · NCT06448130 (registry estimate)
Saxagliptin · Onglyza
Marketed by AstraZeneca and partners
NCT00121667 · Phase 3 · completed
Large randomized, double-blind, placebo-controlled phase 3 trial (743 treated participants across three saxagliptin doses and one placebo arm, all on background metformin). The primary endpoint was change from baseline in hemoglobin A1c at Week 24, an accepted hard glycemic measure for type 2 diabetes, and every saxagliptin dose showed a statistically significant improvement versus placebo (adjusted differences of -0.73, -0.83, and -0.72 percentage points, each p<0.0001). Because the trial was adequately powered, double-blind, and placebo-controlled, and the primary comparison was met, this is strong evidence for saxagliptin's efficacy.
Next expected readout: October 2026 · NCT07033585 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Henagliflozin's landscape · Saxagliptin's landscape